ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
24 hedge funds and large institutions have $6.59M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.
11% less funds holding
Funds holding: 27 → 24 (-3)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
49% less capital invested
Capital invested by funds: $12.8M → $6.59M (-$6.21M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$140K |
| 2 |
VF
Virtu Financial
New York
|
+$33.8K |
| 3 |
Millennium Management
New York
|
+$31.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$16.1K |
| 5 |
Goldman Sachs
New York
|
+$6.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.81M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$140K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$90K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$87K |
| 5 |
Barclays
London,
United Kingdom
|
-$77.2K |
ASLN Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q4 2022, worth a combined $6.59M — down 49% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ASLN and 2 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Citigroup, opening a new position worth an estimated $140K. The largest seller was RTW Investments, exiting entirely with an estimated $1.81M sold.
- 24 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q4 2022, down from 27 in Q3 2022.
- Funds reported $6.59M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q4 2022, down 49% quarter-over-quarter.
- 2 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q4 2022 was Citigroup, an estimated $140K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q4 2022 was RTW Investments, an estimated $1.81M sold.
Based on aggregated 13F filings for Q4 2022.